Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial

Jakob Stokholm, Bo L Chawes, Nadja H Vissing, Elín Bjarnadóttir, Tine M Pedersen, Rebecca K Vinding, Ann-Marie M Schoos, Helene M Wolsk, Sunna Thorsteinsdóttir, Henrik W Hallas, Lambang Arianto, Susanne Schjørring, Karen A Krogfelt, Thea K Fischer, Christian B Pipper, Klaus Bønnelykke, Hans Bisgaard, Jakob Stokholm, Bo L Chawes, Nadja H Vissing, Elín Bjarnadóttir, Tine M Pedersen, Rebecca K Vinding, Ann-Marie M Schoos, Helene M Wolsk, Sunna Thorsteinsdóttir, Henrik W Hallas, Lambang Arianto, Susanne Schjørring, Karen A Krogfelt, Thea K Fischer, Christian B Pipper, Klaus Bønnelykke, Hans Bisgaard

Abstract

Background: Bacteria and viruses are equally associated with the risk of acute episodes of asthma-like symptoms in young children, suggesting antibiotics as a potential treatment for such episodes. We aimed to assess the effect of azithromycin on the duration of respiratory episodes in young children with recurrent asthma-like symptoms, hypothesising that it reduces the duration of the symptomatic period.

Methods: In this randomised, double-blind, placebo-controlled trial, we recruited children aged 1-3 years, who were diagnosed with recurrent asthma-like symptoms from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort; a birth cohort consisting of the general Danish population of Zealand, including Copenhagen. Exclusion criteria were macrolide allergy, heart, liver, neurological, and kidney disease, and, before each treatment, one or more clinical signs of pneumonia (respiratory frequency of ≥50 breaths per min; fever of ≥39°C; C-reactive protein concentration of ≥476·20 nmol/L [≥50 mg/L]). Each episode of asthma-like symptoms lasting at least 3 days was randomly allocated to a 3-day course of azithromycin oral solution of 10 mg/kg per day or placebo after thorough examination by a study physician at the Copenhagen Prospective Studies on Asthma research unit. Each episode was randomly allocated independently of previous treatment from a computer-generated list of random numbers in blocks of ten (generated at the Pharmacy of Glostrup). Investigators and children were masked until the youngest child turned 3 years of age and throughout the data validation and analysis phases. The primary outcome was duration of the respiratory episode after treatment, verified by prospective daily diaries and analysed with Poisson regression. Analyses were per protocol (excluding those without a primary outcome measure or who did not receive treatment). This trial is registered with ClinicalTrials.gov, number NCT01233297.

Findings: Between Nov 17, 2010, and Jan 28, 2014, we randomly allocated 158 asthma-like episodes in 72 children (79 [50%] to azithromycin and 79 [50%] to placebo). The mean duration of the episode after treatment was 3·4 days for children receiving azithromycin compared with 7·7 days for children receiving placebo. Azithromycin caused a significant shortening of the episode of 63·3% (95% CI 56·0-69·3; p<0·0001). The effect size increased with early initiation of treatment, showing a reduction in episode duration of 83% if treatment was initiated before day 6 of the episode compared with 36% if initiated on or after day 6 (p<0·0001). We noted no differences in clinical adverse events between the azithromycin (18 [23%] of 78 episodes included in final analysis) and placebo (24 [30%] of 79) groups (p=0·30), but we did not investigate bacterial resistance patterns after treatment.

Interpretation: Azithromycin reduced the duration of episodes of asthma-like symptoms in young children, suggesting that this drug could have a role in acute management of exacerbations. Further research is needed to disentangle the inflammatory versus antimicrobial aspects of this relation.

Funding: Lundbeck Foundation, Danish Ministry of Health, Danish Council for Strategic Research, Capital Region Research Foundation.

Copyright © 2016 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile Each episode after inclusion was randomly allocated individually.
Figure 2
Figure 2
Duration of episodes of troublesome lung symptoms after treatment
Figure 3
Figure 3
Reduction of duration of episodes of troublesome lung symptoms after azithromycin treatment as a function of episode duration before treatment Circles correspond to estimates and solid lines to 95% pointwise CIs.

References

    1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–478.
    1. Papadopoulos NG, Christodoulou I, Rohde G. Viruses and bacteria in acute asthma exacerbations—a GA2 LEN-DARE systematic review. Allergy. 2011;66:458–468.
    1. Kocevar VS, Bisgaard H, Jönsson L. Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries. Chest. 2004;125:1680–1684.
    1. Bisgaard H, Szefler S. Prevalence of asthma-like symptoms in young children. Pediatr Pulmonol. 2007;42:723–728.
    1. Bush A. Practice imperfect—treatment for wheezing in preschoolers. N Engl J Med. 2009;360:409–410.
    1. Bisgaard H, Hermansen MN, Bønnelykke K. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. BMJ. 2010;341:c4978.
    1. Minor TE, Dick EC, DeMeo AN, Ouellette JJ, Cohen M, Reed CE. Viruses as precipitants of asthmatic attacks in children. JAMA. 1974;227:292–298.
    1. Kusel MM, de Klerk NH, Holt PG, Kebadze T, Johnston SL, Sly PD. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life. Pediatr Infect Dis J. 2006;25:680–686.
    1. Khetsuriani N, Kazerouni NN, Erdman DD. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol. 2007;119:314–321.
    1. Reddel HK, Bateman ED, Becker A. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–639.
    1. Bisgaard H, Vissing NH, Carson CG. Deep phenotyping of the unselected COPSAC2010 birth cohort study. Clin Exp Allergy. 2013;43:1384–1394.
    1. Bischoff AL, Følsgaard NV, Carson CG. Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. PLoS One. 2013;8:e56700.
    1. Bisgaard H, Pipper CB, Bønnelykke K. Endotyping early childhood asthma by quantitative symptom assessment. J Allergy Clin Immunol. 2011;127:1155. 64.e2.
    1. Skytt N, Bønnelykke K, Bisgaard H. ‘To wheeze or not to wheeze’: that is not the question. J Allergy Clin Immunol. 2012;130:403. 07.e5.
    1. Chawes BL, Stokholm J, Bønnelykke K, Brix S, Bisgaard H. Neonates with reduced neonatal lung function have systemic low-grade inflammation. J Allergy Clin Immunol. 2015;135:1450. 56.e1.
    1. Vissing NH, Chawes BL, Bisgaard H. Increased risk of pneumonia and bronchiolitis after bacterial colonization of the airways as neonates. Am J Respir Crit Care Med. 2013;188:1246–1252.
    1. Kreiner-Møller E, Chawes BL, Vissing NH. VEGFA variants are associated with pre-school lung function, but not neonatal lung function. Clin Exp Allergy. 2013;43:1236–1245.
    1. Bisgaard H, Hermansen MN, Buchvald F. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357:1487–1495.
    1. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354:1998–2005.
    1. Bisgaard H, Bønnelykke K, Sleiman PM. Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med. 2009;179:179–185.
    1. Bisgaard H. The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy Asthma Immunol. 2004;93:381–389.
    1. Chawes BL, Buchvald F, Bischoff AL. Elevated exhaled nitric oxide in high-risk neonates precedes transient early but not persistent wheeze. Am J Respir Crit Care Med. 2010;182:138–142.
    1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332:133–138.
    1. Fonseca-Aten M, Okada PJ, Bowlware KL. Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2006;97:457–463.
    1. Schwerk N, Brinkmann F, Soudah B, Kabesch M, Hansen G. Wheeze in preschool age is associated with pulmonary bacterial infection and resolves after antibiotic therapy. PLoS One. 2011;6:e27913.
    1. Jartti T, Kuneinen S, Lehtinen P. Nasopharyngeal bacterial colonization during the first wheezing episode is associated with longer duration of hospitalization and higher risk of relapse in young children. Eur J Clin Microbiol Infect Dis. 2011;30:233–241.
    1. Freymuth F, Vabret A, Brouard J. Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol. 1999;13:131–139.
    1. Biscardi S, Lorrot M, Marc E. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis. 2004;38:1341–1346.
    1. Esposito S, Blasi F, Arosio C. Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J. 2000;16:1142–1146.
    1. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36:646–654.
    1. Koutsoubari I, Papaevangelou V, Konstantinou GN. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol. 2012;23:385–390.
    1. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006;354:1589–1600.
    1. Brusselle GG, Vanderstichele C, Jordens P. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68:322–329.
    1. Brusselle GG, Joos G. Is there a role for macrolides in severe asthma? Curr Opin Pulm Med. 2014;20:95–102.
    1. Le Bourgeois M, Goncalves M, Le Clainche L. Bronchoalveolar cells in children <3 years old with severe recurrent wheezing. Chest. 2002;122:791–797.
    1. Saglani S, Malmström K, Pelkonen AS. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med. 2005;171:722–727.
    1. Beigelman A, Isaacson-Schmid M, Sajol G. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015;135:1171–1178.e1.
    1. Shapiro GG, Eggleston PA, Pierson WE, Ray CG, Bierman CW. Double-blind study of the effectiveness of a broad spectrum antibiotic in status asthmaticus. Pediatrics. 1974;53:867–872.
    1. Graham VA, Milton AF, Knowles GK, Davies RJ. Routine antibiotics in hospital management of acute asthma. Lancet. 1982;1:418–420.
    1. Spreading US macrolide resistance. JAMA. 2015;314:1218.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj